Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses

Journal of Psychopharmacology

Volumn 20, Issue 6 SUPPL., 2006, Pages 20-37

  Turner, Martin S ^a   Stewart, Duncan W ^b  

^a Larkfield Centre   (United Kingdom)

^b Ravenscraig Hospital   (United Kingdom)

Author keywords

Atypical antipsychotic; Compliance; Long acting injectable; Long term efficacy; Maintenance therapy; Psychoses; Relapse; Risperidone; Safety; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE;

AGRANULOCYTOSIS; AKATHISIA; ANXIETY; ANXIETY DISORDER; CLINICAL TRIAL; DIZZINESS; DROWSINESS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DYSTONIA; EMBASE; EVALUATION; GRANULOCYTOPENIA; HEADACHE; HUMAN; HYPERSALIVATION; INJECTION SITE PAIN; INSOMNIA; LONGITUDINAL STUDY; MAINTENANCE THERAPY; MEDLINE; MOTOR DYSFUNCTION; MUSCLE HYPERTONIA; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PARANOIA; PARKINSONISM; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOSIS; PUBLICATION; QUALITY OF LIFE; RELAPSE; REVIEW; SCHIZOPHRENIA; SCHIZOPHRENIC REACTION; SIDE EFFECT; SOMNOLENCE; SYMPTOM; TARDIVE DYSKINESIA; TREMOR; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; DYSKINESIA, DRUG-INDUCED; HUMANS; PATIENT COMPLIANCE; PSYCHOTIC DISORDERS; QUALITY OF LIFE; RECURRENCE; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 33750069720     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/1359786806071243     Document Type: Review

References (65)

1. American Psychiatric Association (1997) American Psychiatric Association: practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry 154: 1-63
2. Andreasen N, Carpenter W, Kane J, Lasser R, Marder S, Weinberger D (2005) Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 162: 441-449
3. Arato M, O'Connor R, Meltzer H Y (2002) A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol 17: 207-215
4. Arvanitis L A, Miller B G (1997) Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 42: 233-246
5. Ayuso-Gutierrez J L, del Rio Vega J M (1997) Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res 28: 199-206
6. Bagnall A M, Jones L, Ginnelly L, Lewis R, Glanville J, Gilbody S, Davies L, Torgerson D, Kleijnen J (2003) A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technol Assess 7: 1-193
7. Bai Y M, Yu S C, Chen J Y, Lin C Y, Chou P, Lin C C (2005) Risperidone for pre-existing severe tardive dyskinesia: a 48-week prospective follow-up study. Int Clin Psychopharmacol 20: 79-85
8. Beasley C, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S (1996) Olanzapine versus placebo and haloperidol. Acute phase results of the North American Double-blind Olanzapine Trial. Neuropsychopharmacology 14: 111-123
9. Beasley Jr C M, Sutton V K, Hamilton S H, Walker D J, Dossenbach M, Taylor C C, Alaka K J, Bykowski D, Tollefson G D (2003) A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. J Clin Psychopharmacol 23: 582-594
10. Bilder R M, Goldman R S, Volavka J, Czobor P, Hoptman M, Sheitman B, Lindenmayer J P, Citrome L, McEvoy J, Kunz M, Chakos M, Cooper T B, Horowitz T L, Lieberman J A (2002) Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 159: 1018-1028
11. Bosveld-van Haandel L, Slooff C J, Van den Bosch R J (2001) Reasoning about the optimal duration of prophylactic antipsychotic medication in schizophrenia: evidence and arguments. Acta Psychiatr Scand 103: 335-346
12. Bunney B (1992) Clozapine: a hypothesised mechanism for its unique clinical profile. Br J Psychiatry 169: 17-21
13. Buse J B, Cavazzoni P, Hornbuckle K, Hutchins D, Breier A, Jovanovic L (2003) A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol 56: 164-170
14. Carpenter Jr W T, Hanlon T E, Heinrichs D W, Summerfeit A T, Kirkpatrick B, Levine J, Buchanan R W (1990) Continuous versus targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry 147: 1138-1148
15. Chan S S, Ungvari G S (2002) Maintenance therapy in schizophrenia: a critical comment. Int J Neuropsychopharmacol 5: 277-281
16. Chue P, Llorca P, Duchesne I, Leal A, Rosillon A, Mehnert A (2005) Hospitalization rates in patients during long-term treatment with long-acting risperidone injection. J Appl Res 5: 266-274
17. Citrome L L (2004) The increase in risk of diabetes mellitus from exposure to second-generation antipsychotic agents. Drugs Today (Barc) 40: 445-464
18. Csernansky J G, Schuchart E K (2002) Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs 16: 473-484
19. Csernansky J G, Mahmoud R, Brenner R (2002) A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 346: 16-22
20. Daniel D G, Wozniak P, Mack R J, McCarthy B G (1998) Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. The Sertindole Study Group. Psychopharmacol Bull 34: 61-69
21. Daniel D G, Zimbroff D L, Potkin S G, Reeves K R, Harrigan E P, Lakshminarayanan M (1999) Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 20: 491-505
22. Davis J M, Chen N, Glick I D (2003) A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60: 553-564
23. Dolder C R, Lacro J P, Dunn L B, Jeste D V (2002) Antipsychotic medication adherence: Is there a difference between typical and atypical agents? Am J Psychiatry 159: 103-108
24. Dossenbach M, Arango-Davila C, Silva Ibarra H, Landa E, Aguilar J, Caro O, Leadbetter J, Assuncao S (2005) Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. J Clin Psychiatry 66: 1021-1030
25. Eerdekens M, Karcher K, Remmerie B, Mannaert E (2004) Pharmacokinetics and tolerability of long-acting injectable risperidone in schizophrenia. Schizophr Res 70: 91-100
26. Fleischhacker W W, Eerdekens M, Karcher K, Remington G, Llorca P M, Chrzanowski W, Martin S, Gefvert O (2003) Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 64: 1250-1257
27. Gaszner P, Makkos Z (2004) Clozapine maintenance therapy in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 28: 465-469
28. Geddes J, Freemantel N, Harrison P, Bebbington P (2000) Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321: 1371-1376.
29. Gerlach J (1999) The continuing problem of extrapyramidal symptoms: strategies for avoidance and effective treatment. J Clin Psychiatry 60 (Suppl. 23): 20-24
30. Herz M I, Glazer W M, Mostert M A, Sheard M A, Szymanski H V, Hafez H, Mirza M, Vana J (1991) Intermittent vs maintenance medication in schizophrenia. Two-year results. Arch Gen Psychiatry 48: 333-339
31. Jablensky A (2000) Prevalence and incidence of schizophrenia spectrum disorders: implications for prevention. Aust N Z J Psychiatry 34 (Suppl.): S26-S34; discussion S35-S38
32. Jibson M D, Tandon R (1998) New atypical antipsychotic medications. J Psychiatr Res 32: 215-228
33. Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45: 789-796
34. Kane J M, Aguglia E, Altamura A C, Ayuso Gutierrez J L, Brunello N, Fleischhacker W W, Gaebel W, Gerlach J, Guelfi J D, Kissling W, Lapierre Y D, Lindstrom E, Mendlewicz J, Racagni G, Carulla L S, Schooler N R (1998) Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol 8: 55-66
35. Kane J M, Carson W H, Saha A R, McQuade R D, Ingenito G G, Zimbroff D L, Ali M W (2002) Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 63: 763-771
36. Kasper S, Brecher M, Fitton L, Jones A M (2004) Maintenance of long-term efficacy and safety of quetiapine in the open-label treatment of schizophrenia. Int Clin Psychopharmacol 19: 281-289
37. Kasper S, Lerman M N, McQuade R D, Saha A, Carson W H, Ali M, Archibald D, Ingenito G, Marcus R, Pigott T (2003) Efficacy and safety of aripiprazole vs haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 6: 325-337
38. Keck Jr P, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan E P, Morrissey M R (1998) Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berl) 140: 173-184
39. Keefe R S, Young C A, Rock S L, Purdon S E, Gold J M, Breier A (2005) One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr Res 81: 1-5
40. Kennedy E, Song F, Hunter R, Clarke A, Gilbody S (2000) Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev: CD000440
41. Lambert T J, Castle D J (2003) Pharmacological approaches to the management of schizophrenia. Med J Aust 178 (Suppl.): S57-S61
42. Lasser R, Bossie C, Gharabawi G, Turner M (2004a) Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. Eur Psychiatry 19: 219-225
43. Lasser R, Bossie C A, Gharabawi G, Eerdekens M, Nasrallah H A (2004b) Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder. J Affect Disord 83: 263-275
44. Lasser R A, Bossie C A, Gharabawi G M, Kane J M (2005) Remission in schizophrenia: results from a 1-year study of long-acting risperidone injection. Schizophr Res 77: 215-227
45. Lasser R, Bossie C A, Zhu Y, Ciliberto N, McLemore J, Kane J M (2004c) Long-acting risperidone in young adults with schizophrenia or schizoaffective disorder. American Psychiatric Association 1-5 May, New York
46. Lasser R A, Bossie C A, Zhu Y, Gharabawi G, Eerdekens M, Davidson M (2004d) Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder. Int J Geriatr Psychiatry 19: 898-905
47. Leucht S, Barnes T R, Kissling W, Engel R R, Correll C, Kane J M (2003) Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 160: 1209-1222
48. Lieberman J A, Phillips M, Gu H, Stroup S, Zhang P, Kong L, Ji Z, Koch G, Hamer R M (2003) Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 28: 995-1003
49. Lieberman J A, Stroup T S, McEvoy J P, Swartz M S, Rosenheck R A, Perkins D O, Keefe R S, Davis S M, Davis C E, Lebowitz B D, Severe J, Hsiao J K (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223
50. Marder S, Meibach R (1994) Risperidone in the treatment of schizophrenia. Am J Psychiatry 151: 825-835
51. Martyns-Yellowe I S (1994) The positive and negative symptoms of schizophrenia: patterns of response to depot neuroleptic treatment. West Afr J Med 13: 200-203
52. Moller H J (1993) Neuroleptic treatment of negative symptoms in schizophrenic patients. Efficacy problems and methodological difficulties. Eur Neuropsychopharmacol 3: 1-11
53. Potkin S G, Saha A R, Kujawa M J, Carson W H, Ali M, Stock E, Stringfellow J, Ingenito G, Marder S R (2003) Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 60: 681-690
54. Rice D (1999) The economic impact of schizophrenia. J Clin Psychiatry 60: 4-6
55. Rodriguez-Perez V, Lopez A, Blanco C, Pena C, Abel A, Gomez Y, Ferreiro M J, Rego C, Cudeiro F, Alvarez V, Prieto R, Ciudad A (2002) Olanzapine for the treatment of chronic refractory schizophrenia: a 12-month follow-up naturalistic study. Prog Neuropsychopharmacol Biol Psychiatry 26: 1055-1062
56. Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey P D, Kopala L, McGorry P D, Van Hove I, Eerdekens M, Swyzen W, De Smedt G (2005) Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 162: 947-953
57. Sernyak M J, Leslie D L, Alarcon R D, Losonczy M F, Rosenheck R (2002) Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 159: 561-566
58. Stanniland C, Taylor D (2000) Tolerability of atypical antipsychotics. Drug Saf 22: 195-214
59. Thieda P, Beard S, Richter A, Kane J (2003) An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv 54: 508-516
60. Tran P V, Dellva M A, Tollefson G D, Wentley A L, Beasley Jr C M, (1998) Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. Br J Psychiatry 172: 499-505
61. Valenstein M, Copeland L A, Owen R, Blow F C, Visnic S (2001) Adherence assessments and the use of depot antipsychotics in patients with schizophrenia. J Clin Psychiatry 62: 545-551
62. van Os J, Bossie C, Lasser R (2004) Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone. Int Clin Psychopharmacol 19: 229-232
63. Weiden P, Olfson M (1995) Cost of relapse in schizophrenia. Schizophr Bull 21: 419-429
64. Whitworth A B, Fleischhacker W W (1995) Adverse effects of antipsychotic drugs. Int Clin Psychopharmacol 9 (Suppl. 5): 21-27
65. Wyatt R (1991) Neuroleptics and the natural course of schizophrenia. Schizophr Bull 17: 325-351